ClinicalTrials.gg
RecruitingNCT07690436Updated Aug 26, 2026

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

An observational study in Transthyretin Amyloid Cardiomyopathy, sponsored by AstraZeneca. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Heart Failure by AstraZeneca — 5 open to participants now, 8 under way, 3 of them phase 3. Heart Failure · AstraZeneca.

Planned enrollment
14th of 25
500 · median 621
Started
2026
with 1 other
Observational
25 of 64
3 open now
Registered
63rd of 64
by date

Among the 64 studies in Heart Failure by AstraZeneca, this one is the 14th largest by planned enrollment of the 25 observational ones that give a count, is one of 2 that started in 2026, is one of 25 observational ones, and was the 63rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 64 studies in Heart Failure by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Heart Failure by AstraZeneca, or all of them as a file.
02

Study summary

This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.

Read the detailed description

A participant who does not complete the study within 90 days from enrollment will be discontinued from the study. A participant may be discontinued from the study at any time at the discretion of the investigator for behavioral or compliance reasons. A participant may withdraw from the study at any time at the participant's own request for any reason (or without providing any reason) without any implication on participant's rights.

03

Conditions studied

  • Transthyretin Amyloid Cardiomyopathy

Browse trials for

Keywords

  • Transthyretin Amyloid Cardiomyopathy
  • ATTR-CM
  • Ocular Imaging
  • Heart Failure
  • Machine Learning
  • Optical coherence tomography
  • Retinal fundus imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will comprise adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls who have documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Participant must be 18 years and older at the time of signing the form.
  • 2. Participants with either of the following:
  • - Positive ATTR-CM cases: Participants with a clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) with amyloid deposits in cardiac or non-cardiac tissue confirmed by Congo Red (or equivalent) staining, or DPD-Tc, PYP-Tc, or HMDP-Tc scintigraphy with Grade 2 or 3 cardiac uptake in the absence of abnormal light chains ratio.
  • - Control population: Participants with a clinical diagnosis of guideline-directed medical therapy-directed heart failure (HF) and either:
  • a) Subgroup A: Definitively excluded ATTR-CM amyloidosis: negative cardiac or non-cardiac tissue for amyloid, or negative technetium scintigraphy within the past 2 years.
  • b) Subgroup B: Low probability of ATTR-CM amyloidosis, not definitively excluded: absence of amyloid-suggestive features on echocardiography (ECHO), electrocardiography (), or cardiac magnetic resonance imaging (MRI) within the past 2 years, with documented clinical assessment indicating HF etiology unlikely attributable to amyloidosis; no amyloid-specific testing (technetium scintigraphy or biopsy) performed.
  • 3. Participant or legally authorized representative (LAR) must sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • 1. Any known eye condition that may preclude clear imaging of the retina.
  • 2. Any known history of amyloid light-chain (AL) amyloidosis.
  • 3. Any ocular surgery that, in the opinion of the investigator, makes participation in the study undesirable.
  • 4. Any medical condition that, in the opinion of the investigator, makes participation in the study undesirable, for example, if the participant is critically unwell or requires ongoing emergency treatment.
  • 5. Involvement in the planning and/or conduct of the study.
  • 6. In the opinion of the investigator, the participant is unlikely to comply with study procedures, restrictions, and requirements.
  • 7. Previous enrollment in the present study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • ATTR-CM

    Participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM).

  • HF Control

    Participants with guideline-directed medical therapy-directed heart failure and documentation within the past 2 years that either excludes transthyretin amyloid cardiomyopathy (ATTR-CM) or indicates a low probability of ATTR-CM.

06

What researchers measure

Primary outcomes

  1. Comparison of per-participant confidence scores distributions between ATTR-CM cases and HF controls without ATTR-CM

    Per-participant confidence score distributions generated by the machine learning (ML) model will be compared between participants with clinically confirmed transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure controls without ATTR-CM.

    Time frame: At a single assessment time point within 90 days following informed consent form signing

  2. Qualitative assessment of features learned indicative of ATTR pathology

    Features learned by the machine learning (ML) model that are indicative of transthyretin amyloid pathology will be qualitatively assessed.

    Time frame: At a single assessment time point within 90 days following informed consent form signing

Secondary outcomes

  1. Sensitivity, specificity, and Area Under the Receiver Operating Characteristic Curve (AUROC) of the ML model to correctly identify ATTR-CM cases based on ocular imaging data

    Sensitivity, specificity, and area under the receiver operating characteristic curve will be used to describe the performance of the machine learning model for distinguishing participants with clinically confirmed transthyretin amyloid cardiomyopathy (ATTR-CM) from heart failure controls without ATTR-CM based on ocular imaging data.

    Time frame: At a single assessment time point within 90 days following informed consent form signing

  2. Descriptive comparison of score distributions across study population strata and demographics

    Score distributions generated by the machine learning model will be descriptively compared across study population strata and demographic groups.

    Time frame: At a single assessment time point within 90 days following informed consent form signing

07

Study locations

1 of 20 sites recruiting
  • Research Site
    Palo Alto, California 94305, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32224, United States
    Not yet recruiting
  • Research Site
    Chicago, Illinois 60611, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    Portland, Oregon 97239-3098, United States
    Not yet recruiting
  • Research Site
    Germantown, Tennessee 38138, United States
    Not yet recruiting
  • Research Site
    Berlin, 13353, Germany
    Not yet recruiting
  • Research Site
    Essen, 45147, Germany
    Not yet recruiting
  • Research Site
    Frankfurt am Main, 60596, Germany
    Not yet recruiting
  • Research Site
    Würzburg, 97078, Germany
    Not yet recruiting
  • Research Site
    Guimarães, 4835-044, Portugal
    Recruiting
  • Research Site
    Lisbon, 1169-024, Portugal
    Not yet recruiting
  • Research Site
    Lisbon, 1649-028, Portugal
    Not yet recruiting
  • Research Site
    Lisbon, 2799-523, Portugal
    Not yet recruiting
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
    Not yet recruiting
  • Research Site
    Madrid, 28040, Spain
    Not yet recruiting
  • Research Site
    Palma de Mallorca, 07198, Spain
    Not yet recruiting
  • Research Site
    Gothenburg, 413 45, Sweden
    Not yet recruiting
  • Research Site
    Solna, 171 64, Sweden
    Not yet recruiting
  • Research Site
    Vasterbottens Lan, 907 37, Sweden
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 8, 2026
StartActual
Jul 8, 2026
Primary completionEst.
Jun 18, 2027
CompletionEst.
Jun 18, 2027
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07690436
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jul 8, 2026
Primary completion
Jun 18, 2027 (estimated)
Completion
Jun 18, 2027 (estimated)
Last update
Aug 26, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion